Realgar-Indigo Naturalis Formulation
Childhood Acute Lymphoblastic Leukemia
Explore 65 assets in Childhood Acute Lymphoblastic Leukemia →Floatz Rating
BB65/100
Confidence
Indicative
Sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Modality
UNKNOWN
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
50Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05682131CT.gov South China Children Cancer Group - Relapsed-Acute Lymphoblastic Leukemia 2022 Protocol | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Indicative
Detailed axis rationale is planned and will be published soon.
Same indication · Childhood Acute Lymphoblastic Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Realgar-Indigo Naturalis Formulation (this asset) | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Approved | BB · 65 |
| Vincristine Sulfate | National Cancer Institute (NCI) | P3 | BBB |
| Cyclophosphamide | St. Jude Children's Research Hospital | P3 | BBB |
| Nivestim | St. Jude Children's Research Hospital | P3 | BBB |
| Cytarabine | Children's Oncology Group | P3 | BBB |
| Mercaptopurine Anhydrous | The Children's Hospital of Zhejiang University School of Medicine | P3 | BBB |
| Etoposide | Martin Schrappe | P3 | BBB |
| Pegaspargase | University of Chicago | P3 | BBB |
| Asparaginase | Therapeutic Advances in Childhood Leukemia Consortium | P3 | BBB |
+42 more in the Childhood Acute Lymphoblastic Leukemia cohort
Other indications for Realgar-Indigo Naturalis Formulation
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Acute Promyelocytic Leukemia | — | P3 | BB · 66 |
| Ovarian Cancer | — | P4 | BB · 65 |
| Acute Myeloid Leukemia | — | P1 | C · 36 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Realgar-Indigo Naturalis Formulation in Childhood Acute Lymphoblastic Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/realgar-indigo-naturalis-formulation-childhood-acute-lymphoblastic-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →